106 Impact of discontinuing hypertonic saline and dornase alfa in people with cystic fibrosis established on elexacaftor-tezacaftor-ivacaftor: A SIMPLIFY ancillary study
Year: 2023
Type: article
Source: Journal of Cystic Fibrosis
Authors: N. Hamblett, A. Gifford, M. Kloster, R. Russell, A. Braun, R. Gibson, J. Hoppe, R. Jain, R. Linnemann, T. Liou, J. Lysinger, C. Milla, J. Young, D. Nichols
Institutions: University of Liverpool, University of Washington, Seattle Children's Research Institute, Johns Hopkins University, University Hospitals Cleveland Medical Center, Indiana University Indianapolis, University of Wisconsin–Madison, Medical University of South Carolina, Case Western Reserve University, The University of Texas Southwestern Medical Center, Emory University, Children's Healthcare of Atlanta, University of Utah, Billings Clinic, Stanford Medicine, Stanford University, Seattle Children's Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4387746184